Fate Therapeutics, Inc.

NasdaqGM:FATE

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

Location

United States

Market Cap

USD 136.41 M

Share Price

USD 1.19

Avg Daily Volume

1,919,220

Change (1 day)

-1.65%

Change (1 year)

-66.85%

Change (YTD)

-27.88%

Fate Therapeutics, Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: -27.88%

Fate Therapeutics, Inc. Share Price Year-To-Date (YTD) return is -27.88% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Fate Therapeutics, Inc. 52-week low Share Price is USD 5.57 on June 20, 2025, which is 368.07% above the current Share Price.
Fate Therapeutics, Inc. 52-week low Share Price is USD 0.68 on June 20, 2025, which is -42.86% below the current Share Price.
Fate Therapeutics, Inc. average Share Price for the last 52 weeks is USD 2.34.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqGM: FATE

Fate Therapeutics, Inc.

CEO	Dr. Bahram Valamehr M.B.A., Ph.D.
IPO Date	Oct. 1, 2013
Location	United States
Headquarters	12278 Scripps Summit Drive
Employees	181
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.